FDA Alters Carcinogenicity Testing of Compounds Used in Food Animals

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

ROCKVILLE, Md-The FDA has amended its regulations for testing the carcinogenicity of compounds used in food-producing animals to eliminate the specific requirement for “oral, chronic, dose-response studies.” The new wording states that bioassays “must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.”

ROCKVILLE, Md—The FDA has amended its regulations for testing the carcinogenicity of compounds used in food-producing animals to eliminate the specific requirement for “oral, chronic, dose-response studies.” The new wording states that bioassays “must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.”

When the existing regulation was issued, chronic studies were the standard. However, advances in carcinogenicity modeling have changed scientists’ views. For example, many researchers now agree that a chronic study “may not measure the appropriate time point necessary to assess carcinogenicity for some compounds,” the FDA said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Related Content